Cefoperazone

{{drugbox | IUPAC_name = (6R,7S)-7-{[2-[(4-ethyl-2,3-dioxo-piperazine-1-
carbonyl)amino]-2-(4-hydroxyphenyl)acetyl}amino]-
3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | image = Cefoperazone.svg | CAS_number = 62893-19-0 | ATC_prefix = J01 | ATC_suffix = DD12 | ATC_supplemental = J01DD62 (WHO) | PubChem = 44185 | DrugBank = | C=25|H=27|N=9|O=8|S=2 | molecular_weight = 645.67 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }} Cefoperazone is a third generation cephalosporin antibiotic. Marketed by pfizer under the name Cefobid^®.

Cefina-SB is a combination of sulbactam and cefoperazone. Cefoperazone exerts its bactericidal effect by inhibiting the bacterial cell wall synthesis, and sulbactam acts as a beta-lactamase inhibitor, to increase the antibacterial activity of cefoperazone against beta-lactamase producing organisms. Cefina-SB is available as injection for the treatment of bacterial infections. In some countries, the combination is sold as Sulperazone. Cefoperazone is available in the United States as Cefobid.

It is one of few cephalosporin antibiotics effective in treating Pseudomonas bacterial infections which are otherwise resistant to these antibiotics.